Search

Your search keyword '"Chapuis, Nicolas"' showing total 432 results

Search Constraints

Start Over You searched for: Author "Chapuis, Nicolas" Remove constraint Author: "Chapuis, Nicolas"
432 results on '"Chapuis, Nicolas"'

Search Results

1. Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents

2. Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation

3. Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms

6. RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia

7. Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients

8. Clinical and biological characteristics of patients presenting with carcinocythaemia: A retrospective, multicentre study by the French‐speaking Cellular Hematology Group (GFHC).

9. Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.

10. COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects

11. Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients

12. White blood cells scattergram as a valuable tool for COVID‐19 screening: A multicentric study.

13. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

14. Along with PaO2/FiO2 ratio and lymphopenia, low HLA-DR monocytes are the only additional parameter that independently predicts the clinical course of undifferentiated SARS-CoV-2 patients in emergency departments

16. Along with PaO2/FiO2 ratio and lymphopenia, low HLA-DR monocytes are the only additional parameter that independently predicts the clinical course of undifferentiated SARS-CoV-2 patients in emergency departments.

17. Neutralizing Antibody Levels as a Correlate of Protection Against SARS‐CoV‐2 Infection: A Modeling Analysis

19. Multicentric Standardized Flow Cytometry Routine Assessment of Patients With Sepsis to Predict Clinical Worsening

21. Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis

23. S162: LOSS OF HEMATOPOIETIC PROGENITORS HETEROGENEITY IS AN ADVERSE PROGNOSTIC FACTOR IN MYELODYSPLASTIC SYNDROMES

24. Along with PaO2/FiO2ratio and lymphopenia, low HLA-DR monocytes are the only additional parameter that independently predicts the clinical course of undifferentiated SARS-CoV-2 patients in emergency departments

25. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes

27. Neutralizing Antibody Levels as a Correlate of Protection Against SARS‐CoV‐2 Infection: A Modeling Analysis.

28. Multiparameter flow cytometry in the evaluation of myelodysplasia:Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group

29. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group

30. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues—Recommendations from the European LeukemiaNet

31. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome:A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

32. Flow cytometric analysis of myelodysplasia:Pre-analytical and technical issues—Recommendations from the European LeukemiaNet

33. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

37. Supplementary Figure Legend, Table 1 from Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

38. Supplementary Figures 1 - 4 from Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

39. Subcutaneous azacitidine maintenance in transplantineligible patients with acute myeloid leukemia: a single-center retrospective study

41. Modelling the association between neutralizing antibody levels and SARS-CoV-2 viral dynamics : implications to define correlates of protection against infection

43. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition

44. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

45. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues

46. AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

47. Rare PNH Cells May be Considered As Genuine PNH Clone: Insights from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

48. DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation

Catalog

Books, media, physical & digital resources